The U.S. drugs regulator on Wednesday asked Pfizer Inc , Eli Lilly & Co and AbbVie Inc to include information about risks of serious conditions and death from the use of a class of treatments known as JAK inhibitors.
to include information about risks of serious conditions and death from the use of a class of treatments known as JAK inhibitors.
The warnings stem from the U.S. Food and Drug Administration's review of Pfizer's arthritis drug Xeljanz after initial results from a February trial showed an increased risk of serious heart-related problems and cancer with the drug. AbbVie shares fell 7%, while Pfizer and Eli Lilly were slightly lower. The companies did not immediately respond to a request for comment.
JAK inhibitors block inflammation-causing enzymes, known as Janus kinases, and target autoimmune diseases such as rheumatoid arthritis and ulcerative colitis. The FDA said the Lilly drug Olumiant and AbbVie's Rinvoq have similar operating mechanisms, leading to the possibility of risks seen in the Xeljanz safety trial.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
More Americans getting vaccinated following full FDA approval of Pfizer COVID vaccineThousands of Americans were persuaded to get their first shot in the week following the Food and Drug Administration's full approval of the Pfizer-BioNtech coronavirus vaccine, new data reveals.
Consulte Mais informação »
U.S. vaccine advisers unanimously favor Pfizer/BioNTech shot after approvalAn advisory panel to the U.S. Centers for Disease Control and Prevention (CDC) on Monday unanimously recommended the Pfizer Inc and BioNTech SE COVID-19 vaccine for people age 16 and older, an important step that could help accelerate vaccine mandates in the United States.
Consulte Mais informação »
More Americans getting vaccinated following full FDA approval of Pfizer COVID vaccineThousands of Americans were persuaded to get their first shot in the week following the Food and Drug Administration's full approval of the Pfizer-BioNtech coronavirus vaccine, new data reveals.
Consulte Mais informação »
U.S. vaccine advisers unanimously favor Pfizer/BioNTech shot after approvalAn advisory panel to the U.S. Centers for Disease Control and Prevention (CDC) on Monday unanimously recommended the Pfizer Inc and BioNTech SE COVID-19 vaccine for people age 16 and older, an important step that could help accelerate vaccine mandates in the United States.
Consulte Mais informação »
Delta damage? Economy added lackluster 374,000 private jobs in August, ADP saysBusinesses in the U.S. created a lackluster 374,000 new jobs in August, a new ADP survey found, suggesting the delta strain of the coronavirus depressed...
Consulte Mais informação »
Amazon pushes deworming drug falsely touted as Covid treatmentThe CDC and FDA have warned against using ivermectin as a treatment for Covid-19.
Consulte Mais informação »